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Background: Treatment of metastatic colorectal cancer (mCRC) has improved due to
the introduction of more active chemotherapies (CT) and novel targeted agents that
have significantly increased response rate (RR), progression free survival (PFS) and
overall survival (OS). Recently, CORRECT and CONCUR trials have demonstrated
both activity and efficacy of regorafenib, a small multi-kinase inhibitor, as
monotherapy in pretreated mCRC. The wide range of action of regorafenib makes it an
ideal candidate for monotherapy in earlier disease treatment lines in which different
pathways could be involved in the acquisition of resistance. To improve long term
efficacy of first line therapy several therapeutic approaches of maintenance treatment
have been explored in mCRC
Material and methods: RAVELLO is an academic randomized, double-blind,
placebo-controlled, multi-center, phase III study designed to evaluate efficacy and
safety of regorafenib as maintenance treatment after first line therapy. Eligible
patients: pathologically confirmed mCRC RAS wild type (KRAS and NRAS genes)
treated with a first line fluoropyrimidine-based CT in combination with an
anti-EGFR (epidermal growth factor receptor) monoclonal antibody for a minimum
of 4 to a maximum of 8 months, with a stratification by response to the first line
treatment (complete response/partial response or stable disease). 480 patients will be
enrolled and randomly assigned in a 1:1 ratio to receive 160 mg regorafenib or
placebo per os, every day for 3 weeks of every 4 weeks cycle, until disease progression
or unacceptable toxicity. Primary endpoint is PFS. With a two-tailed alpha error of
0.05, the study will have 90% power to detect a 3-month prolongation of median PFS
from randomization (corresponding to a hazard ratio of progression of 0.67 with
6-month median PFS expected in the control arm). Secondary endopoint are OS,
safety, and biomarker correlative studies. Fiftheen Italian centers and twenthyone
European centers have been involved in the trial.The First patient was enrolled on
September 2014 at the Second University of Naples. Currently, 4 patients has been
enrolled and are on treatment.
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